Cancer vaccine trial shows promising results in reducing recurrence
A clinical trial combining a custom cancer vaccine with immunotherapy reduced the risk of melanoma recurrence or death by 42%.
A clinical trial combining a custom cancer vaccine with immunotherapy reduced the risk of melanoma recurrence or death by 42%.